CCR1 inhibitors have already entered clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis (Tak et al, 2013) and so have the potential to be tested in a lung cancer setting. The gene discussed is CCR1; the disease is rheumatoid arthritis.